Coronavirus / COVID

Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.

New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.

Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.

Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.

The company's vaccine, mRNA-1283, becomes the first approval under the new federal guidelines.

The World Health Organization (WHO) says the previously predominant LP81 variant has been declining, and that the NB181 strain, which is a variant under monitoring, is increasing.

Following a positive safety review, Vaxart advances its needle-free, room-temperature stable oral vaccine candidate with government-backed funding and a year-long follow-up study.

In a joint announcement, the leaders of the NIH, HHS, and FDA, made comments about this CDC immunization removal.

The FDA committee advisors are recommending the monovalent JN1-lineage-based COVID-19 vaccines preferentially using the LP81 strain.

The company made the decision after the FDA requested more vaccine data for the mRNA-1083 vaccine. Moderna plans to resubmit their Biologics License Application (BLA) for the vaccine later this year.

FDA leadership says they expect more testing for COVID-19 vaccines and that they generate antibody titers in people in order for vaccines to be considered for approval.

The company's Nuvaxovid vaccine is the only recombinant protein-based, non-mRNA COVID-19 immunization available in the US.

Clinical-stage company, Biovie, will study its therapy, bezisterim, for treatment of neurological symptoms associated with the condition. The company expects to have study results in the first half of 2026.

In a large study, Moderna’s investigational vaccine, mRNA-1083, was shown to have noninferiority to other vaccines, and had an acceptable tolerability and safety profile.

Three different studies reveal blood signatures linked to symptoms, immune pathways tied to lung damage, and the efficacy of cognitive training for brain fog.

The company had requested approval for its mRNA-1083 combination vaccine last year. With this setback, the company is now looking at 2026 for approval.

After delays in the review of the COVID-19 vaccine—which missed its April 1 review deadline—the agency has requested new data.

The University of California San Francisco and Gladstone Institutes develop compounds with a 1,000,000-fold reduction in viral titers and 1000 times effective concentration in the brain.

Study of 400,000 pediatric records shows vaccine’s effectiveness in preventing Long COVID during Delta and Omicron waves.

A large study showed these SARS-CoV-2 positive groups were more prone to myocarditis, heart failure, arrhythmias, and chest pain—regardless of prior cardiovascular history or presence of congenital heart disease (CHD).

A new phase 2 trial raises questions about nirmatrelvir-ritonavir’s broader efficacy, as other studies highlight its effectiveness in reducing mortality among immunocompromised COVID-19 patients.

One hospital related the evolution of resistant Acinetobacter baumannii and Pseudomonas aeruginosa in its ICU to the COVID-19 pandemic.

In a new study, Marc Ka-Chun Chong, PhD discusses the antiviral's impact on survival and hospitalization outcomes.

This is the first in a series on the 5 year anniversary of the pandemic. We want to cover a variety of aspects around it, including lessons learned such as testing, vaccine development, and public health policy as well as some ongoing challenges that remain including vaccine hesitancy and an increase in antimicrobial resistant infections.

Shionogi’s investigational antiviral is the first COVID-19 oral therapy that has shown this distinction.

Sarita Shah, MD, MPH, reveals a decline in timely ART initiation from 86.5% in 2019 to 83.9% in 2020, with viral suppression rates dropping from 91.1% to 84.7%, before showing signs of recovery by 2021.

Mia Moore, PhD, presents findings showing 74% reduction in hospitalizations and key insights into primary vaccination and booster impact on population immunity in Washington and Oregon.

Kellie Hawkins, MD discusses the findings along with the challenges of diagnosing Long COVID in people with HIV, emphasizing the need for improved clinical recognition and education.

Annie Antar, MD, PhD, offers insights around her research on her findings on this subject.

Stacy Lindborg, PhD, highlights the vaccine’s immune response, safety, and global distribution potential.